Vpu is the main determinant for tetraspanin downregulation in HIV-1-infected cells

Journal of Virology

Volumn 89, Issue 6, 2015, Pages 3247-3255

  Lambelé, Marie ^a,e   Koppensteiner, Herwig ^c   Symeonides, Menelaos ^a,b   Roy, Nathan H ^a,b,f   Chan, Jany ^a   Schindler, Michael ^c,d   Thali, Markus ^a,b  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF VERMONT   (United States)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^e INSTITUT COCHIN   (France)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD81 ANTIGEN; CD82 ANTIGEN; TETRASPANIN; VPU PROTEIN; CD81 PROTEIN, HUMAN; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; PROTEIN BINDING; VIRAL PROTEIN; VPU PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

ARTICLE; CONTROLLED STUDY; DOWN REGULATION; HOST CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; T LYMPHOCYTE; VIRUS PARTICLE; GENETICS; HOST PATHOGEN INTERACTION; METABOLISM; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTIGENS, CD81; DOWN-REGULATION; HIV INFECTIONS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; PROTEIN BINDING; VIRAL REGULATORY AND ACCESSORY PROTEINS;

EID: 84923165631     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03719-14     Document Type: Article

References (67)

1. Hemler ME. 2005. Tetraspanin functions and associated microdomains. Nat Rev Mol Cell Biol 6:801-811. http://dx.doi.org/10.1038/nrm1736.
2. Yanez-Mo M, Barreiro O, Gordon-Alonso M, Sala-Valdes M, Sanchez-Madrid F. 2009. Tetraspanin-enriched microdomains: a functional unit in cell plasma membranes. Trends Cell Biol 19:434-446. http://dx.doi.org/10.1016/j.tcb.2009.06.004.
3. Charrin S, le Naour F, Silvie O, Milhiet PE, Boucheix C, Rubinstein E. 2009. Lateral organization of membrane proteins: tetraspanins spin their web. Biochem J 420:133-154. http://dx.doi.org/10.1042/BJ20082422.
4. Wright M, Levy S. 2013. Tetraspanins and immunity, p 233-256. In Berditchevski F, Rubinstein E (ed), Tetraspanins. Springer Netherland, Dordrecht, Netherlands.
5. Hemler ME. 2014. Tetraspanin proteins promote multiple cancer stages. Nat Rev Cancer 14:49-60. http://dx.doi.org/10.1038/nrc3640.
6. Hemler ME. 2013. Genetic evidence for tetraspanin functions, p 169-186. In Berditchevski F, Rubinstein E (ed), Tetraspanins. Springer Netherland, Dordrecht, Netherlands.
7. Martin F, Roth DM, Jans DA, Pouton CW, Partridge LJ, Monk PN, Moseley GW. 2005. Tetraspanins in viral infections: a fundamental role in viral biology? J Virol 79:10839-10851. http://dx.doi.org/10.1128/JVI.79 .17.10839-10851.2005.
8. van Spriel AB, Figdor CG. 2010. The role of tetraspanins in the pathogenesis of infectious diseases. Microbes Infect 12:106-112. http://dx.doi .org/10.1016/j.micinf.2009.11.001.
9. Monk PN, Partridge LJ. 2012. Tetraspanins: gateways for infection. Infect Disord Drug Targets 12:4-17. http://dx.doi.org/10.2174/18715 2612798994957.
10. Feneant L, Levy S, Cocquerel L. 2014. CD81 and hepatitis C virus (HCV) infection. Viruses 6:535-572. http://dx.doi.org/10.3390/v6020535.
11. Scheffer KD, Berditchevski F, Florin L. 2014. The tetraspanin CD151 in papillomavirus infection. Viruses 6:893-908. http://dx.doi.org/10.3390/v6020893.
12. Meerloo T, Parmentier HK, Osterhaus AD, Goudsmit J, Schuurman HJ. 1992. Modulation of cell surface molecules during HIV-1 infection of H9 cells. An immunoelectron microscopic study. AIDS 6:1105-1116.
13. Meerloo T, Sheikh MA, Bloem AC, de Ronde A, Schutten M, van Els CA, Roholl PJ, Joling P, Goudsmit J, Schuurman HJ. 1993. Host cell membrane proteins on human immunodeficiency virus type 1 after in vitro infection of H9 cells and blood mononuclear cells. An immunoelectron microscopic study. J Gen Virol 74:129-135.
14. Orentas RJ, Hildreth JE. 1993. Association of host cell surface adhesion receptors and other membrane proteins with HIV and SIV. AIDS Res Hum Retroviruses 9:1157-1165. http://dx.doi.org/10.1089/aid.1993.9.1157.
15. Thali M. 2011. Tetraspanin functions during HIV-1 and influenza virus replication. Biochem Soc Trans 39:529-531. http://dx.doi.org/10.1042/BST0390529.
16. Nydegger S, Khurana S, Krementsov DN, Foti M, Thali M. 2006. Mapping of tetraspanin-enriched microdomains that can function as gateways for HIV-1. J Cell Biol 173:795-807. http://dx.doi.org/10.1083/jcb.200508165.
17. Chertova E, Chertov O, Coren LV, Roser JD, Trubey CM, Bess JW, Jr, Sowder RC, II, Barsov E, Hood BL, Fisher RJ, Nagashima K, Conrads TP, Veenstra TD, Lifson JD, Ott DE. 2006. Proteomic and biochemical analysis of purified human immunodeficiency virus type 1 produced from infected monocyte-derived macrophages. J Virol 80:9039-9052. http://dx .doi.org/10.1128/JVI.01013-06.
18. Jolly C, Sattentau QJ. 2007. Human immunodeficiency virus type 1 assembly, budding, and cell-cell spread in T cells take place in tetraspaninenriched plasma membrane domains. J Virol 81:7873-7884. http://dx.doi .org/10.1128/JVI.01845-06.
19. Ott DE. 2008. Cellular proteins detected in HIV-1. Rev Med Virol 18: 159-175. http://dx.doi.org/10.1002/rmv.570.
20. Sato K, Aoki J, Misawa N, Daikoku E, Sano K, Tanaka Y, Koyanagi Y. 2008. Modulation of human immunodeficiency virus type 1 infectivity through incorporation of tetraspanin proteins. J Virol 82:1021-1033. http://dx.doi.org/10.1128/JVI.01044-07.
21. Ono A. 2010. Relationships between plasma membrane microdomains and HIV-1 assembly. Biol Cell 102:335-350. http://dx.doi.org/10.1042/BC20090165.
22. Krementsov DN, Rassam P, Margeat E, Roy NH, Schneider-Schaulies J, Milhiet PE, Thali M. 2010. HIV-1 assembly differentially alters dynamics and partitioning of tetraspanins and raft components. Traffic 11:1401-1414. http://dx.doi.org/10.1111/j.1600-0854.2010.01111.x.
23. Hogue IB, Grover JR, Soheilian F, Nagashima K, Ono A. 2011. Gag induces the coalescence of clustered lipid rafts and tetraspanin-enriched microdomains at HIV-1 assembly sites on the plasma membrane. J Virol 85:9749-9766. http://dx.doi.org/10.1128/JVI.00743-11.
24. Ruiz-Mateos E, Pelchen-Matthews A, Deneka M, Marsh M. 2008. CD63 is not required for production of infectious human immunodeficiency virus type 1 in human macrophages. J Virol 82:4751-4761. http://dx.doi .org/10.1128/JVI.02320-07.
25. Chen H, Dziuba N, Friedrich B, von Lindern J, Murray JL, Rojo DR, Hodge TW, O'Brien WA, Ferguson MR. 2008. A critical role for CD63 in HIV replication and infection of macrophages and cell lines. Virology 379:191-196. http://dx.doi.org/10.1016/j.virol.2008.06.029.
26. Grigorov B, Attuil-Audenis V, Perugi F, Nedelec M, Watson S, Pique C, Darlix JL, Conjeaud H, Muriaux D. 2009. A role for CD81 on the late steps of HIV-1 replication in a chronically infected T cell line. Retrovirology 6:28. http://dx.doi.org/10.1186/1742-4690-6-28.
27. Krementsov DN, Weng J, Lambele M, Roy NH, Thali M. 2009. Tetraspanins regulate cell-to-cell transmission of HIV-1. Retrovirology 6:64. http://dx.doi.org/10.1186/1742-4690-6-64.
28. Li G, Endsley MA, Somasunderam A, Gbota SL, Mbaka MI, Murray JL, Ferguson MR. 2014. The dual role of tetraspanin CD63 in HIV-1 replication. Virol J 11:23. http://dx.doi.org/10.1186/1743-422X-11-23.
29. Weng J, Krementsov DN, Khurana S, Roy NH, Thali M. 2009. Formation of syncytia is repressed by tetraspanins in human immunodeficiency virus type 1-producing cells. J Virol 83:7467-7474. http://dx.doi.org/10 .1128/JVI.00163-09.
30. Symeonides M, Lambele M, Roy NH, Thali M. 2014. Evidence showing that tetraspanins inhibit HIV-1-induced cell-cell fusion at a post-hemifusion stage. Viruses 6:1078-1090. http://dx.doi.org/10 .3390/v6031078.
31. Feldmann J, Schwartz O. 2010. HIV-1 Virological synapse: live imaging of transmission. Viruses 2:1666-1680. http://dx.doi.org/10.3390/v2081666.
32. Chen BK. 2012. T cell virological synapses and HIV-1 pathogenesis. Immunol Res 54:133-139. http://dx.doi.org/10.1007/s12026-012-8320-8.
33. Roy NH, Lambele M, Chan J, Symeonides M, Thali M. 2014. Ezrin is a component of the HIV-1 virological presynapse and contributes to the inhibition of cell-cell fusion. J Virol 88:7645-7658. http://dx.doi.org/10 .1128/JVI.00550-14.
34. Vasiliver-Shamis G, Dustin ML, Hioe CE. 2010. HIV-1 virological synapse is not simply a copycat of the immunological synapse. Viruses 2:1239-1260. http://dx.doi.org/10.3390/v2051239.
35. Janvier K, Bonifacino JS. 2005. Role of the endocytic machinery in the sorting of lysosome-associated membrane proteins. Mol Biol Cell 16: 4231-4242. http://dx.doi.org/10.1091/mbc.E05-03-0213.
36. Schindler M, Munch J, Kirchhoff F. 2005. Human immunodeficiency virus type 1 inhibits DNA damage-triggered apoptosis by a Nefindependent mechanism. J Virol 79:5489-5498. http://dx.doi.org/10 .1128/JVI.79.9.5489-5498.2005.
37. Wehrly K, Chesebro B. 1997. p24 antigen capture assay for quantification of human immunodeficiency virus using readily available inexpensive reagents. Methods 12:288-293. http://dx.doi.org/10.1006/meth.1997.0481.
38. Banning C, Votteler J, Hoffmann D, Koppensteiner H, Warmer M, Reimer R, Kirchhoff F, Schubert U, Hauber J, Schindler M. 2010. A flow cytometry-based FRET assay to identify and analyse protein-protein interactions in living cells. PLoS One 5:e9344. http://dx.doi.org/10.1371/journal.pone.0009344.
39. Koppensteiner H, Banning C, Schneider C, Hohenberg H, Schindler M. 2012. Macrophage internal HIV-1 is protected from neutralizing antibodies. J Virol 86:2826-2836. http://dx.doi.org/10.1128/JVI.05915-11.
40. Lindwasser OW, Chaudhuri R, Bonifacino JS. 2007. Mechanisms of CD4 downregulation by the Nef and Vpu proteins of primate immunodeficiency viruses. Curr Mol Med 7:171-184. http://dx.doi.org/10.2174/156652407780059177.
41. Malim MH, Emerman M. 2008. HIV-1 accessory proteins- ensuring viral survival in a hostile environment. Cell Host Microbe 3:388-398. http://dx.doi.org/10.1016/j.chom.2008.04.008.
42. Tokarev A, Guatelli J. 2011. Misdirection of membrane trafficking by HIV-1 Vpu and Nef: keys to viral virulence and persistence. Cell Logist 1:90-102. http://dx.doi.org/10.4161/cl.1.3.16708.
43. Wildum S, Schindler M, Munch J, Kirchhoff F. 2006. Contribution of Vpu, Env, and Nef to CD4 down-modulation and resistance of human immunodeficiency virus type 1-infected T cells to superinfection. J Virol 80:8047-8059. http://dx.doi.org/10.1128/JVI.00252-06.
44. Chen BK, Gandhi RT, Baltimore D. 1996. CD4 down-modulation during infection of human T cells with human immunodeficiency virus type 1 involves independent activities of vpu, env, and nef. J Virol 70:6044-6053.
45. Haller C, Muller B, Fritz JV, Lamas-Murua M, Stolp B, Pujol FM, Keppler OT, Fackler OT. 2014. HIV-1 Nef and Vpu are functionally redundant broad-spectrum modulators of cell surface receptors, including tetraspanins. J Virol 88:14241-14257. http://dx.doi.org/10.1128/JVI .02333-14.
46. Schubert U, Strebel K. 1994. Differential activities of the human immunodeficiency virus type 1-encoded Vpu protein are regulated by phos-phorylation and occur in different cellular compartments. J Virol 68: 2260-2271.
47. Van Damme N, Goff D, Katsura C, Jorgenson RL, Mitchell R, Johnson MC, Stephens EB, Guatelli J. 2008. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 3:245-252. http://dx.doi.org/10.1016/j.chom.2008.03.001.
48. Levesque K, Zhao YS, Cohen EA. 2003. Vpu exerts a positive effect on HIV-1 infectivity by down-modulating CD4 receptor molecules at the surface of HIV-1-producing cells. J Biol Chem 278:28346-28353. http://dx.doi.org/10.1074/jbc.M300327200.
49. Pizzato M, Helander A, Popova E, Calistri A, Zamborlini A, Palu G, Gottlinger HG. 2007. Dynamin 2 is required for the enhancement of HIV-1 infectivity by Nef. Proc Natl Acad Sci U S A 104:6812-6817. http://dx.doi.org/10.1073/pnas.0607622104.
50. Bregnard C, Zamborlini A, Leduc M, Chafey P, Camoin L, Saib A, Benichou S, Danos O, Basmaciogullari S. 2013. Comparative proteomic analysis of HIV-1 particles reveals a role for Ezrin and EHD4 in the Nefdependent increase of virus infectivity. J Virol 87:3729-3740. http://dx .doi.org/10.1128/JVI.02477-12.
51. Basmaciogullari S, Pizzato M. 2014. The activity of Nef on HIV-1 infectivity. Front Microbiol 5:232. http://dx.doi.org/10.3389/fmicb.2014 .00232.
52. Dube M, Bego MG, Paquay C, Cohen EA. 2010. Modulation of HIV-1-host interaction: role of the Vpu accessory protein. Retrovirology 7:114. http://dx.doi.org/10.1186/1742-4690-7-114.
53. Andrew A, Strebel K. 2010. HIV-1 Vpu targets cell surface markers CD4 and BST-2 through distinct mechanisms. Mol Aspects Med 31:407-417. http://dx.doi.org/10.1016/j.mam.2010.08.002.
54. Yoshimori T, Yamamoto A, Moriyama Y, Futai M, Tashiro Y. 1991. Bafilomycin A1, a specific inhibitor of vacuolar-type H(+)-ATPase, inhibits acidification and protein degradation in lysosomes of cultured cells. J Biol Chem 266:17707-17712.
55. Tsubuki S, Saito Y, Tomioka M, Ito H, Kawashima S. 1996. Differential inhibition of calpain and proteasome activities by peptidyl aldehydes of di-leucine and tri-leucine. J Biochem 119:572-576. http://dx.doi.org/10 .1093/oxfordjournals.jbchem.a021280.
56. Landi A, Iannucci V, Nuffel AV, Meuwissen P, Verhasselt B. 2011. One protein to rule them all: modulation of cell surface receptors and molecules by HIV Nef. Curr HIV Res 9:496-504. http://dx.doi.org/10.2174/157016211798842116.
57. Casartelli N, Sourisseau M, Feldmann J, Guivel-Benhassine F, Mallet A, Marcelin AG, Guatelli J, Schwartz O. 2010. Tetherin restricts productive HIV-1 cell-to-cell transmission. PLoS Pathog 6:e1000955. http://dx.doi .org/10.1371/journal.ppat.1000955.
58. Jolly C, Booth NJ, Neil SJ. 2010. Cell-cell spread of human immunodeficiency virus type 1 overcomes tetherin/BST-2-mediated restriction in T cells. J Virol 84:12185-12199. http://dx.doi.org/10.1128/JVI.01447-10.
59. Bolduan S, Reif T, Schindler M, Schubert U. 2014. HIV-1 Vpu mediated downregulation of CD155 requires alanine residues 10, 14 and 18 of the transmembrane domain. Virology 464-465:375-384. http://dx.doi.org/10 .1016/j.virol.2014.07.034.
60. Dube M, Roy BB, Guiot-Guillain P, Mercier J, Binette J, Leung G, Cohen EA. 2009. Suppression of Tetherin-restricting activity upon human immunodeficiency virus type 1 particle release correlates with localization of Vpu in the trans-Golgi network. J Virol 83:4574-4590. http://dx .doi.org/10.1128/JVI.01800-08.
61. Hauser H, Lopez LA, Yang SJ, Oldenburg JE, Exline CM, Guatelli JC, Cannon PM. 2010. HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment. Retrovirology 7:51. http://dx.doi.org/10.1186/1742-4690-7-51.
62. Ramirez PW, Famiglietti M, Sowrirajan B, DePaula-Silva AB, Rodesch C, Barker E, Bosque A, Planelles V. 2014. Downmodulation of CCR7 by HIV-1 Vpu results in impaired migration and chemotactic signaling within CD4(+) T cells. Cell Rep 7:2019-2030. http://dx.doi.org/10.1016/j.celrep.2014.05.015.
63. Strebel K. 2013. HIV accessory proteins versus host restriction factors. Curr Opin Virol 3:692-699. http://dx.doi.org/10.1016/j.coviro.2013.08 .004.
64. Kahrstrom CT. 2014. Viral pathogenesis: Vpu puts the brakes on ADCC. Nat Rev Microbiol 12:397. http://dx.doi.org/10.1038/nrmicro3282.
65. Rocha-Perugini V, Zamai M, Gonzalez-Granado JM, Barreiro O, Tejera E, Yanez-Mo M, Caiolfa VR, Sanchez-Madrid F. 2013. CD81 controls sustained T cell activation signaling and defines the maturation stages of cognate immunological synapses. Mol Cell Biol 33:3644-3658. http://dx .doi.org/10.1128/MCB.00302-13.
66. Hong IK, Byun HJ, Lee J, Jin YJ, Wang SJ, Jeoung DI, Kim YM, Lee H. 2014. The Tetraspanin CD81 protein increases melanoma cell motility by up-regulating metalloproteinase MT1-MMP expression through the prooncogenic Akt-dependent Sp1 activation signaling pathways. J Biol Chem 289:15691-15704. http://dx.doi.org/10.1074/jbc.M113.534206.
67. Tsai YC, Weissman AM. 2011. Dissecting the diverse functions of the metastasis suppressor CD82/KAI1. FEBS Lett 585:3166-3173. http://dx .doi.org/10.1016/j.febslet.2011.08.031.